Loading cancer entity…
Loading cancer entity…
Clinical trials
359 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (52)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03317795 | Treatment of Heavy Menstrual Bleeding in Women With Uterine Fibroids | completed | Phase 4 | 18 | Shannon K. Laughlin-TommasoOTHER | 1 | Dec 8, 2021 | clinicaltrials |
| NCT04030182 | Vitamin D Deficit in Women With Uterine Fibroids | completed | — | 127 | Instituto Mexicano del Seguro SocialOTHER_GOV | 1 | Nov 8, 2021 | clinicaltrials |
| NCT04672421 |
| The Efficacy and Safety of Medicurtain® in Patients With Total Laparoscopic Hysterectomy (Pivotal Study) |
| completed |
| N/A |
| 107 |
| Shin Poong Pharmaceutical Co. Ltd.INDUSTRY |
| 1 |
| Sep 29, 2021 |
| clinicaltrials |
| NCT04819633 | Evaluating Serum Sestrin in Leiomyoma Patients | completed | — | 61 | Sisli Hamidiye Etfal Training and Research HospitalOTHER | 1 | Sep 21, 2021 | clinicaltrials |
| NCT00731341 | Hysteroscopic Cryomyolysis for the Treatment of Submucosal Leiomyomata | completed | N/A | 3 | Boston Scientific CorporationINDUSTRY | 1 | Jul 19, 2021 | clinicaltrials |
| NCT01441635 | Safety and Efficacy of Elagolix in Pre-Menopausal Women With Heavy Uterine Bleeding and Uterine Fibroids | completed | Phase 2 | 271 | AbbVie (prior sponsor, Abbott)INDUSTRY | 0 | Jul 13, 2021 | clinicaltrials |
| NCT02925494 | An Extension Study to Evaluate the Efficacy and Safety of Elagolix in Premenopausal Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids | completed | Phase 3 | 433 | AbbVieINDUSTRY | 3 | Jul 13, 2021 | clinicaltrials |
| NCT03070899 | Efficacy and Safety of OBE2109 in Subjects With Heavy Menstrual Bleeding Associated With Uterine Fibroids(PRIMROSE 1) | completed | Phase 3 | 526 | ObsEva SAINDUSTRY | 1 | Jun 9, 2021 | clinicaltrials |
| NCT04832906 | UA Versus UAE in Treatment of Fibroids | completed | Phase 4 | 70 | Ain Shams Maternity HospitalOTHER | 1 | Apr 6, 2021 | clinicaltrials |
| NCT03070951 | Efficacy and Safety of OBE2109 in Subjects With Heavy Menstrual Bleeding Associated With Uterine Fibroids(PRIMROSE 2) | completed | Phase 3 | 511 | ObsEva SAINDUSTRY | 9 | Mar 5, 2021 | clinicaltrials |
| NCT03021720 | Satisfaction of Patients With Trans-Arterial Radial Access: Quality of Life in Uterine Fibroid Embolization Trial(SPARQLE) | completed | N/A | 40 | Mount Sinai Hospital, CanadaOTHER | 1 | Feb 25, 2021 | clinicaltrials |
| NCT03444987 | The Role of Fibroblast Activation in Uterine Fibroid | completed | — | 35 | Assiut UniversityOTHER | 1 | Feb 9, 2021 | clinicaltrials |
| NCT01840124 | Uterine Leiomyoma Treatment With Radiofrequency Ablation(ULTRA) | completed | N/A | 26 | University of California, San FranciscoOTHER | 1 | Jan 25, 2021 | clinicaltrials |
| NCT01338831 | Phase I Study of LFA102 in Patients With Prolactin Receptor-positive Castration-resistant Prostate Cancer or Prolactin Receptor-positive Metastatic Breast Cancer | completed | Phase 1 | 73 | Novartis PharmaceuticalsINDUSTRY | 4 | Dec 17, 2020 | clinicaltrials |
| NCT02260752 | Patient Centered Results for Uterine Fibroids(COMPARE-UF) | completed | — | 3,094 | Duke UniversityOTHER | 1 | Nov 18, 2020 | clinicaltrials |
| NCT03744507 | Bone Mineral Density in Women With Uterine Fibroids or Endometriosis | completed | — | 660 | Myovant Sciences GmbHINDUSTRY | 7 | Nov 10, 2020 | clinicaltrials |
| NCT04576039 | Ultrasonographic Appearance of the Endometrium After Ulipristalacetate Use and Endometrial Changes | completed | N/A | 10 | Universitair Ziekenhuis BrusselOTHER | 1 | Oct 5, 2020 | clinicaltrials |
| NCT03535610 | Uterine Artery Embolization With Microspheres in Patients With Leiomyoma.(EMBOSOFT I) | completed | N/A | 32 | Scitech Produtos Medicos SAINDUSTRY | 1 | Sep 4, 2020 | clinicaltrials |
| NCT03270605 | Myomectomy During CS: A Retrospective Cohort Study | completed | — | 178 | Mansoura UniversityOTHER | 0 | Sep 1, 2020 | clinicaltrials |
| NCT01817530 | Safety and Efficacy in Premenopausal Women With Heavy Menstrual Bleeding (HMB) Associated With Uterine Fibroids (UF) | completed | Phase 2 | 571 | AbbVieINDUSTRY | 0 | Jul 21, 2020 | clinicaltrials |
| NCT01846520 | Family Caregiver Palliative Care Intervention in Supporting Caregivers of Patients With Stage II-IV Gastrointestinal, Gynecologic, Urologic and Lung Cancers | completed | N/A | 200 | City of Hope Medical CenterOTHER | 1 | Jan 23, 2020 | clinicaltrials |
| NCT03328260 | High Intensity Focused Ultrasound in Uterine Myoma | completed | N/A | 34 | Seoul National University HospitalOTHER | 1 | Jan 3, 2020 | clinicaltrials |
| NCT03411980 | Pharmacokinetics and Safety of Vilaprisan in Renal Impairment | completed | Phase 1 | 26 | BayerINDUSTRY | 1 | Dec 3, 2019 | clinicaltrials |
| NCT02096783 | Scripted Sexual Health Informational Intervention in Improving Sexual Function in Patients With Gynecologic Cancer | completed | N/A | 15 | University of Wisconsin, MadisonOTHER | 1 | Nov 18, 2019 | clinicaltrials |
| NCT02470741 | Pilot of Letrozole for Uterine Myomas(PLUM) | completed | Phase 4 | 12 | University of California, San FranciscoOTHER | 1 | Nov 15, 2019 | clinicaltrials |
| NCT01377519 | Magnetic Resonance Guided Focused Ultrasound for Uterine Fibroids(PROMISe) | completed | N/A | 20 | University of California, San FranciscoOTHER | 1 | Nov 5, 2019 | clinicaltrials |
| NCT02844920 | Evaluation of Uterine Patency Following Sonography-guided Transcervical Ablation of Fibroids(OPEN) | completed | — | 37 | GynesonicsINDUSTRY | 4 | Sep 20, 2019 | clinicaltrials |
| NCT04091529 | Tailored Radiofrequency Ablation of Uterine Myomas | completed | N/A | 54 | International Evangelical HospitalOTHER | 1 | Sep 18, 2019 | clinicaltrials |
| NCT03427671 | OCL 500 Treatment of Women With Symptomatic Uterine Fibroids | completed | N/A | 12 | IMBiotechnologies Ltd.INDUSTRY | 1 | Sep 12, 2019 | clinicaltrials |
| NCT01629563 | PGL4001 Efficacy Assessment in Reduction of Symptoms Due to Uterine Leiomyomata(PEARLIV) | completed | Phase 3 | 451 | PregLem SAINDUSTRY | 11 | Sep 4, 2019 | clinicaltrials |
| NCT01168232 | Ixabepilone in Treating Patients With Recurrent or Persistent Uterine Cancer | completed | Phase 2 | 42 | National Cancer Institute (NCI)NIH | 1 | Aug 8, 2019 | clinicaltrials |
| NCT01220609 | Ixabepilone in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus Previously Treated With Chemotherapy | completed | Phase 2 | 26 | National Cancer Institute (NCI)NIH | 1 | Aug 8, 2019 | clinicaltrials |
| NCT01247571 | Pazopanib Hydrochloride in Treating Patients With Recurrent or Persistent Uterine Cancer | completed | Phase 2 | 22 | National Cancer Institute (NCI)NIH | 1 | Aug 8, 2019 | clinicaltrials |
| NCT00339547 | Risk Factors for Uterine Fibroids: A Case Control Study | completed | — | 1,529 | National Institute of Environmental Health Sciences (NIEHS)NIH | 1 | Jul 25, 2019 | clinicaltrials |
| NCT00025506 | Thalidomide in Treating Patients With Recurrent or Persistent Carcinosarcoma of the Uterus | completed | Phase 2 | 55 | National Cancer Institute (NCI)NIH | 1 | Jul 24, 2019 | clinicaltrials |
| NCT00075400 | Imatinib Mesylate in Treating Patients With Recurrent or Persistent Uterine Cancer | completed | Phase 2 | 26 | National Cancer Institute (NCI)NIH | 1 | Jul 24, 2019 | clinicaltrials |
| NCT00025220 | Thalidomide in Treating Patients With Recurrent or Persistent Cancer of the Uterus | completed | Phase 2 | 60 | National Cancer Institute (NCI)NIH | 1 | Jul 23, 2019 | clinicaltrials |
| NCT00378911 | Sunitinib in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus | completed | Phase 2 | 44 | National Cancer Institute (NCI)NIH | 1 | Jul 23, 2019 | clinicaltrials |
| NCT01637961 | Alisertib in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus | completed | Phase 2 | 23 | National Cancer Institute (NCI)NIH | 1 | Jul 23, 2019 | clinicaltrials |
| NCT02889848 | Safety and Tolerability of Collagenase Clostridium Histolyticum (EN3835) to Treat Uterine Leiomyoma (Fibroids) | completed | Phase 1 | 15 | Advance Biofactures CorporationINDUSTRY | 1 | Jul 10, 2019 | clinicaltrials |
| NCT02323646 | Safety and Efficacy of Telapristone Acetate (Proellex®) Administered Vaginally for the Treatment of Uterine Fibroids | completed | Phase 2 | 42 | Repros Therapeutics Inc.INDUSTRY | 1 | Jun 25, 2019 | clinicaltrials |
| NCT00958334 | Extension Study of Proellex in Women Who Have Previously Completed Study ZPU 003 | completed | Phase 2 | 65 | Repros Therapeutics Inc.INDUSTRY | 1 | Jun 18, 2019 | clinicaltrials |
| NCT00341848 | Postpartum Uterine Regression | completed | — | 374 | National Institute of Environmental Health Sciences (NIEHS)NIH | 1 | Jun 17, 2019 | clinicaltrials |
| NCT03072446 | Uterine Fibroid Embolization (UFE) for Symptomatic Fibroids: Comparison of Gel-Bead to Commonly Used Embolic Agents. | completed | N/A | 11 | University Hospital Southampton NHS Foundation TrustOTHER | 1 | May 9, 2019 | clinicaltrials |
| NCT02655224 | A Placebo-Controlled, Phase 3 Study of Relugolix (TAK-385) 40 mg in the Treatment of Pain Symptoms Associated With Uterine Fibroids | completed | Phase 3 | 65 | TakedaINDUSTRY | 1 | Mar 22, 2019 | clinicaltrials |
| NCT02655237 | A Phase 3 Study to Evaluate the Efficacy and Safety of Relugolix (TAK-385) 40 mg Compared With Leuprorelin in the Treatment of Uterine Fibroids | completed | Phase 3 | 281 | TakedaINDUSTRY | 1 | Mar 22, 2019 | clinicaltrials |
| NCT01142791 | Safety Study of ExAblate for the Treatment of Uterine Fibroids | completed | N/A | 121 | InSightecINDUSTRY | 1 | Mar 19, 2019 | clinicaltrials |
Data updated 22 days agoSource updated Dec 8, 2021source: clinicaltrials